Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2016
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Brain injuries; Hyponatraemia
- Focus Pharmacokinetics
- 06 Sep 2016 Status changed from recruiting to discontinued.
- 01 Dec 2015 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 01 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.